June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Centile-based analysis of refractive development in the MiSight® 1 day Myopia Control trial.
Author Affiliations & Notes
  • Daniel Ian Flitcroft
    Childrens University Hospital, Dublin, Dublin 1, Ireland
    Technological University Dublin, Ireland
  • James Loughman
    Technological University Dublin, Ireland
  • Baskar Arumugam
    Coopervision, Inc., California, United States
  • Arthur Bradley
    Coopervision, Inc., California, United States
  • Paul Chamberlain
    Coopervision, Inc., California, United States
  • Footnotes
    Commercial Relationships   Daniel Flitcroft, Coopervision (C), Technological University Dublin (P); James Loughman, Coopervision (C), Technological University Dublin (P); Baskar Arumugam, Coopervision (E); Arthur Bradley, Coopervision (E); Paul Chamberlain, Coopervision (E)
  • Footnotes
    Support  MRCO-2016-13, Health Research Board, Fighting Blindness, Ireland.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1372. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel Ian Flitcroft, James Loughman, Baskar Arumugam, Arthur Bradley, Paul Chamberlain; Centile-based analysis of refractive development in the MiSight® 1 day Myopia Control trial.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1372.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To employ centile analysis for assessing the treatment efficacy of a clinical trial for myopia control, and to quantify differences in the natural history of myopia progression in the treatment group, control group and conventional clinical practice.

Methods : Gender and age specific population centiles for refraction and annual progression were calculated for the 113 subjects recruited for the MiSight® 1 day trial (Chamberlain et al., OVS 2019) in Western trial sites (Portugal, United Kingdom and Canada). The reference population used for centile calculation comprised 4650 Irish children aged 8-17, from an anonymized sample of optometric health records where refraction data was available over multiple visits (mean 5.32, range 3-23).

Results : The partial MiSight control group showed no significant change in centile values of spherical equivalent refraction over three years (mean change -0.9, 95% CI -2.8 to 1.1) indicating that they were following the natural history pattern seen in the population based sample, whereas the treatment group showed a change of -10.7 (95% CI -12.7 to -8.7, Fig. 1). First year annual myopic progression in the control group was similar to that seen in the population sample with a mean centile of 58.4 (95% CI 53.3 to 63.5). In the treatment group the mean progression centile value was significantly lower at 32.6 in year 1 (95% CI 26.9 to 38.4), a difference that persisted over the three years of the trial (Wilcoxon, P= 0.027). Histograms of progression centiles show that the treatment group displayed a reduction in fast progressors, an effect present in both young (<= median age) and older subjects (> median age) (Kolmogorov-Smirnov two-sided test, treatment vs control young P < 0.00001, older group P < 0.0005, Fig. 2).

Conclusions : This analysis indicates that the MiSight lens can alter the natural history of myopia. There was a reduction in the proportion of fast progressors in both the younger and older treated subjects. Population based centile analysis offers the prospect of monitoring the treatment efficacy of myopia control interventions outside a clinical trial and allows individual clinical practice patients to be benchmarked against the results obtained during the MiSight trial.

This is a 2020 ARVO Annual Meeting abstract.

 

Figure 1: 3 year change in Spherical Equivalent Refraction Centile, Control vs Treatment

Figure 1: 3 year change in Spherical Equivalent Refraction Centile, Control vs Treatment

 

Figure 2: Centiles for annual myopic progression, Control vs Treatment for younger and older subjects

Figure 2: Centiles for annual myopic progression, Control vs Treatment for younger and older subjects

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×